arrow
Return
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Nature Reviews Drug Discovery cover
Nature Reviews Drug Discovery
IF:
101.8
Papers:
5.1K
Citations:
5.3W

Organization

M
Massachusetts General Hospital
Scholars:
3.4W
Papers: 2.6W
Citations: 8.6W
H
Harvard University
Scholars:
26.5W
Papers: 22.0W
Citations: 28.7W
Cited Papers

Cited Papers

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
err2010-10-28
err3.9K
errOAAI
errKwak, Eunice L.; Bang, Yung-Jue; Camidge, D. Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Jaenne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, S. Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John
errShare
errSave
Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition
err1991-02-01
err0
PREAI
errG.J. Miller; J.C. Martin; K.A. Mitropoulos; B.E.A. Reeves; R.L. Thompson; T.W. Meade; J.A. Cooper; J.K. Cruickshank
errShare
errSave
Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
err2010-06-15
err248
PREAI
errJanku, Filip; Stewart, David J.; Kurzrock, Razelle
errShare
errSave
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
err2010-10-28
err1.0K
errOAAI
errChoi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki
errShare
errSave
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
err2008-05-01
err384
errOAAI
errMcDermott, Ultan; Lafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey
errShare
errSave
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
err2007-05-04
err736
errOAAI
errZou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.
errShare
errSave
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
err2011-08-18
err857
PREAI
errCui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Quhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.
errShare
errSave
no more